{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:56:45Z","timestamp":1786982205253,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T00:00:00Z","timestamp":1285632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9682-1","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T14:32:52Z","timestamp":1285597972000},"page":"39-47","source":"Crossref","is-referenced-by-count":19,"title":["Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group"],"prefix":"10.1007","volume":"28","author":[{"given":"Ruta D.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody A.","family":"Cobleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Mark L.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Thomas","family":"Budd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,28]]},"reference":[{"key":"9682_CR1","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","volume":"351","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451\u201367.","journal-title":"Lancet"},{"issue":"suppl 3","key":"9682_CR2","first-page":"S59","volume":"8","author":"ML Cobleigh","year":"1994","unstructured":"Cobleigh ML. Breast cancer and fenretinide, an analogue of vitamin A. Leukemia. 1994;8 (suppl 3):S59\u201363.","journal-title":"Leukemia."},{"key":"9682_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0277-5379(91)90471-O","volume":"27","author":"RG Mehta","year":"1991","unstructured":"Mehta RG, Moon RC, Hawthorne M, et al. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer. 1991;27:138\u201341.","journal-title":"Eur J Cancer"},{"key":"9682_CR4","first-page":"1339","volume":"39","author":"RC Moon","year":"1979","unstructured":"Moon RC, Thompson HJ, Becci PJ, et al. N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 1979;39:1339\u201346.","journal-title":"Cancer Res"},{"key":"9682_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0304-3835(89)90089-X","volume":"47","author":"K Dowlatshahi","year":"1989","unstructured":"Dowlatshahi K, Mehta R, Thomas C, et al. Therapeutic effect of N-(4-hydroxyphenyl) retinamide on N-methyl-N-nitrosurea-induced rat mammary cancer. Cancer Lett. 1989;47:187\u201392.","journal-title":"Cancer Lett"},{"key":"9682_CR6","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/carcin\/10.9.1645","volume":"10","author":"RC Moon","year":"1989","unstructured":"Moon RC, Pritchard JF, Mehta RG, et al. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl) retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis. 1989;10:1645\u20139.","journal-title":"Carcinogenesis"},{"key":"9682_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/carcin\/20.8.1535","volume":"20","author":"A Green","year":"1999","unstructured":"Green A, Shilkaitis A, Christov K. 4-(Hydroxyphenyl) retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. Carcinogenesis. 1999;20:1535\u201340.","journal-title":"Carcinogenesis"},{"key":"9682_CR8","first-page":"4472","volume":"49","author":"TA Ratko","year":"1989","unstructured":"Ratko TA, Detrisac CJ, Dinger NM, et al. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 1989;49:4472\u20136.","journal-title":"Cancer Res"},{"key":"9682_CR9","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/jnci\/91.21.1847","volume":"91","author":"U Veronesi","year":"1999","unstructured":"Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent secondary breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847\u201356.","journal-title":"J Natl Cancer Inst"},{"key":"9682_CR10","first-page":"508","volume":"42","author":"DL McCormick","year":"1982","unstructured":"McCormick DL, Mehta RG, Thompson CA, et al. Enhanced inhibition of mammary carcinogenesis by combined treatment with 4-HPR and ovariectomy. Cancer Res. 1982;42:508\u201312.","journal-title":"Cancer Res"},{"key":"9682_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/1097-0142(19830215)51:4<594::AID-CNCR2820510407>3.0.CO;2-Y","volume":"51","author":"DL McCormick","year":"1983","unstructured":"McCormick DL, Sowell ZL, Thompson CA, et al. Inhibition by retinoid and ovariectomy of additional primary malignancies in rats following surgical removal of the first mammary cancer. Cancer. 1983;51:594\u20139.","journal-title":"Cancer"},{"key":"9682_CR12","first-page":"3095","volume":"40","author":"C Welsch","year":"1980","unstructured":"Welsch C, Brown C, Goodrich-Smith, et al. Synergistic effect of chronic prolactin suppression and retinoid treatment in the prophylaxis of N-methyl-N-nitrosurea-induced mammary tumorigenesis in female Sprague-Dawley rats. Cancer Res. 1980;40:3095\u20138.","journal-title":"Cancer Res"},{"key":"9682_CR13","first-page":"6635","volume":"4","author":"GT Budd","year":"1998","unstructured":"Budd GT, Adamson PC, Gupta M, et al. Phase I\/II trial of all-trans-retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res. 1998;4:6635\u201342.","journal-title":"Clin Cancer Res"},{"key":"9682_CR14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.1993.11.3.474","volume":"11","author":"MA Cobleigh","year":"1993","unstructured":"Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. Phase I\/II Trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J Clin Oncol. 1993;11:474\u20137.","journal-title":"J Clin Oncol"},{"key":"9682_CR15","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/jnci\/87.22.1655","volume":"87","author":"J Lotan","year":"1995","unstructured":"Lotan J. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst. 1995;87:1655\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"9682_CR16","unstructured":"Seewaldt VL, Johnson BS, Parker MB, et al. Expression of the retinoic acid receptor \u03b2 mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 6:1077\u201388."},{"key":"9682_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0304-3835(96)04344-3","volume":"107","author":"TT Wang","year":"1996","unstructured":"Wang TT, Phang JM. Effect of N-(4-hydroxyphenyl) retinamide on apoptosis in human breast cancer cells. Cancer Lett. 1996;107:65\u201371.","journal-title":"Cancer Lett"},{"key":"9682_CR18","first-page":"2493","volume":"59","author":"SY Sun","year":"1999","unstructured":"Sun SY, Li W, Yue P, et al. Mediation of N-(4-hydroxyphenyl) retinamide induced apoptosis in human cancer cells by different mechanisms. Cancer Res. 1999;59:2493\u20138.","journal-title":"Cancer Res"},{"key":"9682_CR19","first-page":"1892","volume":"5","author":"RK Srivastava","year":"1999","unstructured":"Srivastava RK, Srivastava AR, Cho-Chug YS, et al. Synergistic effects of retinoic acid and 8-chloro-adenosine 3\u2032,5\u2032-cyclic monophosphate on the regulation of retinoic acid receptor \u03b2 and apoptosis: involvement of mitochondria. Clin Cancer Res. 1999;5:1892\u2013904.","journal-title":"Clin Cancer Res"},{"key":"9682_CR20","first-page":"855","volume":"2","author":"N Oridate","year":"1996","unstructured":"Oridate N, Lotan D, Xu XC, et al. Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 1996;2:855\u201363.","journal-title":"Clin Cancer Res"},{"key":"9682_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1006\/excr.2002.5582","volume":"279","author":"M Poot","year":"2002","unstructured":"Poot M, Hosier S, Swisshelm K. Distinct patterns of mitochondrial changes precede induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in MCF7 breast cancer cells. Exp Cell Res. 2002;279:128\u201340.","journal-title":"Exp Cell Res"},{"key":"9682_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1038\/bjc.1998.358","volume":"77","author":"R Favoni","year":"1998","unstructured":"Favoni R, de Cupis A, Bruno S, et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer. 1998;77:2138\u201347.","journal-title":"Br J Cancer"},{"key":"9682_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","volume":"351","author":"SE Hankinson","year":"1998","unstructured":"Hankinson SE, Willet WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet. 1998;351:1393\u20136.","journal-title":"Lancet"},{"key":"9682_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<787::AID-IJC3>3.0.CO;2-U","volume":"76","author":"R Torrisi","year":"1998","unstructured":"Torrisi R, Parodi S, Fontana V, et al. Effect of fenretinide on plasma IGF-I and iGFBP-3 in early breast cancer patients. Int J Cancer. 1998;76:787\u201390.","journal-title":"Int J Cancer"},{"key":"9682_CR25","first-page":"4722","volume":"9","author":"A Decensi","year":"2003","unstructured":"Decensi A, Veronesi U, Miceli R, et al. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res. 2003;9:4722\u20139.","journal-title":"Clin Cancer Res"},{"key":"9682_CR26","first-page":"1047","volume":"10","author":"A Decensi","year":"2001","unstructured":"Decensi A, Johansson H, Miceli R, et al. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1047\u201353.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"9682_CR27","volume-title":"AJCC cancer staging manual","author":"American Joint Committee on Cancer","year":"1997","unstructured":"American Joint Committee on Cancer. AJCC cancer staging manual. Philadelphia, PA: Lippincott-Raven; 1997."},{"key":"9682_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0021-9681(74)90015-0","volume":"27","author":"M Zelen","year":"1974","unstructured":"Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365\u201375.","journal-title":"J Chronic Dis"},{"key":"9682_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2307\/2281868","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"9682_CR30","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163\u201370.","journal-title":"Cancer Chemother Rep"},{"key":"9682_CR31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc Ser B. 1972;34:187\u2013220.","journal-title":"J R Stat Soc Ser B"},{"key":"9682_CR32","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1200\/JCO.2008.19.3797","volume":"27","author":"A Decensi","year":"2009","unstructured":"Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. Randomized double-blind 2 x 2 trial of low-dose Tamoxifen and Fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol. 2009;27:3749\u201356.","journal-title":"J Clin Oncol"},{"key":"9682_CR33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/030089169608200506","volume":"82","author":"L Mariani","year":"1996","unstructured":"Mariani L, Formelli F, De Palo G, et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long term visual and ophthalmologic tolerability. Tumori. 1996;82:444\u20139.","journal-title":"Tumori"},{"key":"9682_CR34","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2001.19.6.1664","volume":"19","author":"T Camerini","year":"2001","unstructured":"Camerini T, Mariani L, De Palo G, et al. Safety of the synthetic retinoid fenretinide: Long-term results from a controlled clinical trial for the prevention of contralateral breast cancer. J Clin Oncol. 2001;19:1664\u201370.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9682-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9682-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9682-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T21:56:32Z","timestamp":1740520592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9682-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,28]]},"references-count":34,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9682"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9682-1","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,28]]}}}